Podcast appearances and mentions of peter loftus

Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ's Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts.  Further Listening: Trillion Dollar Shot  Why WeightWatchers Wants in on Drugs Like Ozempic   Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

P.M. Edition for Nov. 26. Israel approves a cease-fire with Hezbollah in Lebanon. WSJ chief economics commentator Greg Ip makes sense of President-elect Donald Trump's threat to hit trade allies Canada and Mexico with steep tariffs. Pharma reporter Peter Loftus explains why a highly anticipated obesity-drug candidate disappointed investors. And retail reporter Sarah Nassauer discusses Walmart's reversal on its DEI initiatives. Tracie Hunte hosts.  Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

A.M. Edition for Oct. 21. The WSJ's Niharika Mandhana says the U.S. is racing to upgrade far-flung airfields in the Pacific as a way to defend against China's enormous missile arsenal. Plus, Elon Musk offers a $1 million daily prize to a randomly chosen registered voter who has signed a petition by his America PAC. And, after a slow start, the WSJ's Peter Loftus says Johnson & Johnson's bet on a ketamine-derived drug to treat depression is paying off. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The 2024 presidential race is taking on a familiar tone — with Democrats accusing Republicans of wanting to ban abortion and repeal the Affordable Care Act and Republicans insisting they have no such plans. Voters will determine whom they believe. Meanwhile, for the second time in a month, a state judge overturned an abortion ban, but few expect the decision to settle the matter. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Anna Edney of Bloomberg News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News' Lauren Sausser, who reported and wrote the latest KFF Health News-Washington Post “Bill of the Month,” about a teenage athlete whose needed surgery lacked a billing code. Plus, for “extra credit,” the panelists suggest health policy stories they read this week that they think you should read, too: Julie Rovner: KFF Health News' “Doctors Urging Conference Boycotts Over Abortion Bans Face Uphill Battle,” by Ronnie Cohen. Anna Edney: Bloomberg News' “A Free Drug Experiment Bypasses the US Health System's Secret Fees,” by John Tozzi. Alice Miranda Ollstein: The Wall Street Journal's “Hospitals Hit With IV Fluid Shortage After Hurricane Helene,” by Joseph Walker and Peter Loftus. Sandhya Raman: The Asheville Citizen Times' “Without Water After Helene, Residents at Asheville Public Housing Complex Fear for Their Health,” by Jacob Biba. Hosted on Acast. See acast.com/privacy for more information.

 A.M. Edition for Sept. 23. Israel and Hezbollah intensify their cross-border attacks, bringing them as close to full-out war as they have been in their nearly year-long conflict. Plus, chip giants TSMC and Samsung discuss building megafactories in the United Arab Emirates. And, Novo Nordisk and Eli Lilly dangle big discounts for their weight-loss drugs. The WSJ's Peter Loftus explains who stands to win in this price war. Azhar Sukri hosts.  Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Subscribe to UnitedHealthcare's Community & State newsletter.Health Affairs' Jeff Byers welcomes Senior Editor Leslie Erdelack to the program to discuss FDA's recent approval of an Alzheimer's treatment drug, Lilly's Kisunla, how private insurers and Medicare may cover the drug, and the emerging new class of drugs surrounding Alzheimer's treatment.We announced the winner for our You're A Health Policy Wonk If... contest this week!Until July 20, we are having a flash sale on Health Affairs Insider membership. Use the code HealthWonkLife for $30 off the normal Insider price.Check out our Request For Abstracts page for the April 2025 theme issue focusing on Food, Nutrition, and Health.Related Articles:Approval of Newest Alzheimer's Drug Will Accelerate New Era of Treatment by Peter Loftus and Joseph Walker (Wall Street Journal)Press Release: Lilly's Kisunla Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease Subscribe to UnitedHealthcare's Community & State newsletter.

Today we're presenting Trillion Dollar Shot, a new series that explores the business story behind the rise of Ozempic and other blockbuster drugs being used for weight loss. The first episode focuses on the Novo Nordisk scientist who invented the compound that paved the way for Ozempic. You can find every episode on The Journal's show feed. Trillion Dollar Shot is part of The Journal, which is a co-production of Spotify and the Wall Street Journal. This episode was hosted by Jessica Mendoza, with Bradley Olson. It was produced by Matt Kwong, with help from Jeevika Verma. Additional production from Adrienne Murray Nielsen. The series is edited by Katherine Brewer. Sound design and mixing by Peter Leonard. Mixing for Science Vs by Bobby Lord. Music in this episode by Peter Leonard and Bobby Lord. Theme music by So Wylie, remixed for this series by Peter Leonard. Special thanks to Maria Byrne, Stefanie Ilgenfritz, Kate Linebaugh, Peter Loftus, Sara O'Brien, Enrique Perez De La Rosa, Sarah Platt, Sune Rasumssen, Jonathan Sanders, Nathan Singhapok, Leying Tang, Rolfe Winkler, Liz Essley Whyte, and Tatiana Zamis. Learn more about your ad choices. Visit podcastchoices.com/adchoices

P.M. Edition for May 24. A group of Jeep and Ram brand dealers recently vented their frustration to Stellantis executives about high sticker prices keeping buyers at bay. Ryan Felton has more. And Eli Lilly makes the biggest investment in its history to ramp up production of its hot-selling weight-loss drugs. Peter Loftus reports. Plus, the U.N.'s International Court of Justice orders Israel to halt some military operations in Gaza. Pierre Bienaimé hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Social media platforms are full of posts by influencers talking up the latest generation of weight-loss drugs like Ozempic. And it's causing people to seek out the drugs, in some cases displacing doctors as the trusted authorities on whether to take one of the medicines. WSJ special writer Peter Loftus tells host Alex Ossola about what happens when social media and weight loss drugs overlap. Plus, a hack into healthcare technology company Change Healthcare has been called the most serious incident of its kind to strike the industry. Now, its parent company is digging into what happened. WSJ Pro Deputy Bureau Chief Kim Nash talks about the attack. Listening on Google Podcasts? Here's our guide for switching to a different podcast player. Learn more about your ad choices. Visit megaphone.fm/adchoices

People with health-insurance plans could face thousands of dollars in prescription-drug costs per year as they pay down their deductible. Wall Street Journal reporter Peter Loftus joins host J.R. Whalen to discuss ways to reduce your drug spending in 2024. Learn more about your ad choices. Visit megaphone.fm/adchoices

P.M. Edition for Nov. 8. Some drugmakers are setting two prices for the same drug. And many health plans are choosing the more expensive version, according to data analysis conducted for the WSJ. Pharmaceutical reporter Peter Loftus explains why. Plus, three companies—including one run by a former NYSE president—are vying for collapsed cryptocurrency exchange FTX at auction. Markets reporter Vicky Ge Huang explains. Annmarie Fertoli hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

A.M. Edition for Aug. 3. More U.S. employers are cutting off access to popular weight-loss treatments for workers as spending on the drugs leaps into the tens of millions of dollars for insurance plans. Journal pharmaceutical reporter Peter Loftus explains what that means for patients and drugmakers. Plus, a wave of strikes on Ukrainian ports threaten the world's food supply. And fresh jitters in China's property market. Luke Vargas hosts. Learn more about your ad choices. Visit megaphone.fm/adchoices

A warning from the Treasury Department that the U.S. could default on its debt as soon as June 1 has galvanized lawmakers to intervene. But there is still no obvious way to reconcile Republican demands to slash federal spending with President Joe Biden's demand to raise the debt ceiling and save the spending fight for a later date. Meanwhile, efforts to pass abortion bans in conservative states are starting to stall as some Republicans rebel against the most severe bans. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Alice Miranda Ollstein of Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too:Julie Rovner: The Washington Post's “Dog-Walking Injuries May Be More Common Than You Think,” by Lindsey Bever. Joanne Kenen: The Atlantic's “There Is No Stopping the Allergy Apocalypse,” by Yasmin Tayag. Rachel Cohrs: ProPublica's “This Pharmacist Said Prisoners Wouldn't Feel Pain During Lethal Injection. Then Some Shook and Gasped for Air,” by Lauren Gill and Daniel Moritz-Rabson.Alice Miranda Ollstein: The Wall Street Journal's “Patients Lose Access to Free Medicines Amid Spat Between Drugmakers, Health Plans,” by Peter Loftus and Joseph Walker. Hosted on Acast. See acast.com/privacy for more information.

In this episode of Throwback FDNY...in 1865, the Maltese cross is introduced as a symbol of the fire department. In 1948, Peter Loftus is appointed Chief of Department. And in 1967, a gas leak causes a 13-alarm fire in Queens.

The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World by Peter Loftus The inside story of an unprecedented feat of science and business. At the start of 2020, Moderna was a biotech unicorn with dim prospects. Yes, there was the promise of its disruptive innovation that could transform medicine by using […] The post The Chris Voss Show Podcast – The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World by Peter Loftus appeared first on Chris Voss Official Website.

The hot weight-loss drug Wegovy is in short supply and high demand.  The drug has proven to help people lose as much as 15% of their weight by suppressing appetite, but the company expected a more gradual adoption of the drug and has lost out on a ton of potential cash.  Selling only $700 million to date, analysts had projected $2 billion in sales for 2021 and 2022.  Peter Loftus, pharma reporter at the WSJ, joins us for why you can't find Wegovy.   Next, the Real ID requirement for air travel has been delayed once again.  Americans will have two more years, until May 2025 to go to the DMV and provide the proper paperwork.  The deadline was extended to help DMVs with pandemic related setbacks.  To date, only about 49% of people have gotten their updated IDs.  Luz Lazo, transportation reporter at The Washington Post, joins us for what to know.   Finally, a pair of marijuana bills may be attached to “must-pass” year-end bills in Congress.  A bipartisan group of senators will be trying to add the SAFE Banking Act to allow cannabis businesses to access loans and open bank accounts and the HOPE Act, which would provide grants to states that expunge former convictions.  Sophia Cai, congressional reporter at Axios, joins us for the plan to pass pot legislation.See omnystudio.com/listener for privacy information.

The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World by Peter Loftus The inside story of an unprecedented feat of science and business. At the start of 2020, Moderna was a biotech unicorn with dim prospects. Yes, there was the promise of its disruptive innovation that could transform medicine by using something called messenger RNA, one of the body's building blocks of life, to combat disease. But its stock was under water. There were reports of a toxic work culture. And despite ten years of work, the company was still years away from delivering its first product. Investors were getting antsy, or worse, skeptical. Then the pandemic hit, and Moderna, at first reluctantly, became a central player in a global drama—a David to Big Pharma's Goliaths—turning its technology toward breaking the global grip of the terrible disease. By year's end, with the virus raging, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement gave the world a way out of a crippling pandemic while validating Moderna's technology, transforming the company into a global industry power. Biotech, and the venture capital community that fuels it, will never be the same. Wall Street Journal reporter Peter Loftus, veteran reporter covering the pharmaceutical and biotech industries and part of a Pulitzer Prize–finalist team, brings the inside story of Moderna, from its humble start at a casual lunch through its heady startup days, into the heart of the pandemic and beyond. With deep access to all of the major players, Loftus weaves a tale of science and business that brings to life Moderna's monumental feat of creating a vaccine that beat back a deadly virus and changed the business of medicine forever. The Messenger spans a decade and is full of heroic efforts by ordinary people, lucky breaks, and life-and-death decisions. It's the story of a revolutionary idea, the evolution of a cutting-edge American industry, and one of the great achievements of this century.

Even though Pfizer-BioNTech's Messenger RNA-based COVID vaccine was released first; it is Moderna's vaccine and the relatively unknown company's journey to billions of dollars in profits that piqued the interest of Wall Street Journal reporter, Peter Loftus, who writes about it in his new book, "The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World". Listen now to find out why.

Even though Pfizer-BioNTech's Messenger RNA-based COVID vaccine was released first; it is Moderna's vaccine and the relatively unknown company's journey to billions of dollars in profits that piqued the interest of Wall Street Journal reporter, Peter Loftus, who writes about it in his new book, "The Messenger: Moderna, the Vaccine, and the Business Gamble That Changed the World". Listen now to find out why.

Does any CEO deserve $500 million a year? How did Moderna hit it big? And who wants to run Biogen? STAT's Bob Herman joins us to explain why health care CEOs get paid so much — and why company-reported numbers don't tell the full story. Wall Street Journal reporter Peter Loftus calls in to talk about his book chronicling how Moderna went from secretive startup to household name. And we discuss the latest news in the life sciences, including Amazon's latest multibillion-dollar foray into primary care and Biogen's search for a new CEO.

WNBA star Brittney Griner has been detained in a Russian prison since Feb. 17 when she was caught at an airport near Moscow with hash oil in vape cartridges.  She is on trial right now where a guilty verdict could carry a sentence of 10 years.  Her best hope of getting out could be a prisoner exchange, but the U.S. has long been wary of these and the DOJ usually opposes them.  Louise Radnofsky, sports reporter at the WSJ, joins us for what to know. Next, there are now enough doses of vaccine available globally to vaccinate all adults and children, but the demand has dropped so much that governments, vaccination sites, and even the drugmakers themselves are having to dispose of millions of doses.  One of the main problems is that vaccines are packaged in multi-dose vials, and once they're opened, the rest must be discarded if not used in 12 hours.  Peter Loftus, Pharma reporter at the WSJ, joins us for how the supply has now outstripped the demand. Finally, Lake Mead has shrunk to record lows.  The reservoir supplies electricity to 350,000 homes as well as irrigation and drinking water to 25 million people.  But as the water levels continue to drop, people are more interested finding barrels with bodies or jewelry and other treasures that were once hidden.  Joshua Partlow, reporter at the Washington Post, joins us for more. See omnystudio.com/listener for privacy information.

There are now enough doses of vaccine available globally to vaccinate all adults and children, but the demand has dropped so much that governments, vaccination sites, and even the drugmakers themselves are having to dispose of millions of doses.  One of the main problems is that vaccines are packaged in multi-dose vials, and once they're opened, the rest must be discarded if not used in 12 hours.  Peter Loftus, Pharma reporter at the WSJ, joins us for how the supply has now outstripped the demand. See omnystudio.com/listener for privacy information.

P.M. Edition for July 6. Millions of doses of Covid-19 vaccines, once in high demand, are going unused. Drugmakers and health authorities say supply is outstripping demand. WSJ pharmaceutical reporter Peter Loftus joins host Annmarie Fertoli discuss. Learn more about your ad choices. Visit megaphone.fm/adchoices

Falling in line with what we heard from Pfizer's mRNA vaccine, Moderna has released interim data showing that their vaccine is also safe and produced the desired immune response in children ages 6-11. The dosage would be half of what it is for adults, but still come in a 2-shot protocol. Peter Loftus, pharmaceutical reporter at the WSJ, joins us for what to expect as the vaccines get closer to being approved for children. Next, remember all those vaccine lotteries? It went something like this… get you vaccine and you're automatically entered to win a million bucks. 19 states in total ran some type of lottery and spent at least $89 million, unfortunately, they didn't work too well. Research says that the increases were “very small in magnitude and statistically indistinguishable from zero.” Erin Schumaker, science editor at Business Insider, joins us for more. Finally, for those that enjoy a good night out dancing with friends or having a drink, you may be asking when you can enjoy nightlife again. The pandemic changed a lot, but as things open up more, it is all about accessing your personal risk. Clubs and bars are after all perfect places to spread Covid with crowds of people and poor ventilation. Alex Abad-Santos, senior correspondent at Vox, joins us for what to know. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

A new coronavirus vaccine may soon be available from Novavax as they say their two-dose shot is 90% effective at preventing symptomatic Covid-19. While it may not make much of an impact in the U.S., it is expected to be a welcome addition to global vaccination efforts. Approval may still take a few months as they ramp up their manufacturing processes, but it is still a big win for Novavax who has never won an approval for a vaccine. Peter Loftus, pharmaceutical reporter at the WSJ, joins us for what to know. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Hoy en Día a Día, comenzamos conversando con Enrique Serbeto, corresponsal de ABC en Bruselas, sobre el inicio de la cumbre de la OTAN: “Todos estaban felices de que EE.UU, el país más importante de la OTAN, volviera a esta canción del multilateralismo híbrido entre aliados… Ahora se ha pasado al ‘America is back'”, dijo. También destacó que “EE.UU y Europa se necesitan para hacer frente al desafío que suponen Rusia y China, países que ponen en peligro sus intereses”. La reportera de inmigración de El Paso Times y USA TODAY, Lauren Villagran, nos habló sobre la posible reapertura de la frontera común entre México y Estados Unidos: “La Casa Blanca ha creado un grupo de trabajo para analizar cuáles son las condiciones necesarias para esta reapertura”, dijo, y destacó que “Los residentes han podido cruzar por cualquier razón desde siempre, mientras que nuestros hermanos mexicanos que tienen visa no han podido cruzar”. Luis Izquiel, abogado y coautor del libro ‘Revolución de la Muerte: 20 años de Crimen, Violencia e Impunidad en Venezuela', abordó el tema de las megabandas criminales en Caracas: “El Estado venezolano abandonó los sectores populares, y se creó un vacío de poder, el cual fue llenado por estos líderes criminales”, dijo, y además comentó que “Los cuerpos de seguridad perdieron la capacidad para controlar a estos fenómenos de crimen organizado”. Desde Philadelphia nos atendió Peter Loftus, reportero farmacéutico de The Wall Street Journal, con quien hablamos sobre la nueva vacuna de Novavax: “La vacuna tiene 96% de efectividad contra el Covid-19 originario, y es igual de efectiva contra otras variantes… Es de dos dosis, con un período de 3 semanas entre una y otra”, comentó. Loftus contó que “Novavax ha hecho gestiones con los gobiernos de diferentes países y ha entrado en contacto con el mecanismo Covax para distribuir 1 millón de vacunas”. Sobre las detenciones a líderes opositores nicaragüenses, conversamos con Marcos Medina, director del portal web Fuentes Confiables, quien nos dijo: “La última semana se ha registrado la detención de 15 líderes de oposición, entre ellos 4 precandidatos presidenciales… El gobierno ha alegado que estas detenciones se dan en base a las normativas aprobadas por la AN: la Ley de Agentes Extranjeros y la Ley de Defensa de los Derechos del Pueblo”. Y para cerrar, el corresponsal del diario La Nación, Darío Palavecino, nos habló sobre el profesor en Argentina que abusó de una venezolana con la falsa promesa de encontrarle trabajo: “El hombre le propinó cierta situación de abrigo, y comenzó a seducirla, hasta que se convierte en una situación de abuso… El hombre era profesor y tenía a su cargo a alumnas adolescentes, y tenía en casa encerrada a esta joven, de la que abusaba diariamente”, nos contó. “Cuando el caso sale a la luz, llega a la Justicia Federal otra joven venezolana que dice haber pasado por la misma situación, en el mismo lugar y con el mismo abusador, pero en el 2018”, agregó.

Matt and Dara are joined by Vox's Dylan Matthews to talk about what the Covid vaccine development process has taught us vaccine development, production, and regulation. They also discuss the way we fund scientific research, evaluating a possible "prize"-based alternative to our current grant-funding system, and some research is analyzed that concerns the resiliency of so-called "forced entrepreneurs," and their businesses' tendency to better weather recessions. Resources: "How to supercharge vaccine production for the next pandemic" by Dylan Matthews (May 20; Vox) "Inside Moderna: The Covid Vaccine Front-Runner With No Track Record and an Unsparing CEO" by Peter Loftus and Gregory Zuckerman (July 1, 2020; Wall Street Journal) "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race" by Damian Garde and Jonathan Saltzman (Nov. 10, 2020; STAT News) "Science funding is a mess. Could grant lotteries make it better?" by Kelsey Piper (Jan. 18, 2019; Vox) White paper Hosts: Matt Yglesias (@mattyglesias), Slowboring.com Dara Lind (@DLind), Immigration Reporter, ProPublica Dylan Matthews (@dylanmatt), Senior Correspondent, Vox Credits: Erikk Geannikis, Editor and Producer As the Biden administration gears up, we'll help you understand this unprecedented burst of policymaking. Sign up for The Weeds newsletter each Friday: vox.com/weeds-newsletter. The Weeds is a Vox Media Podcast Network production. Want to support The Weeds? Please consider making a contribution to Vox: bit.ly/givepodcasts About Vox Vox is a news network that helps you cut through the noise and understand what's really driving the events in the headlines. Follow Us: Vox.com Facebook group: The Weeds Learn more about your ad choices. Visit podcastchoices.com/adchoices

The FDA this week approved a controversial drug to help treat depression and it the first new antidepressant to be greenlit in decades.  It is a nasal spray branded as Spravato made by Johnson and Johnson and is very similar to Ketamine. The benefit of this nasal spray is its fast acting impact on depression symptoms. Peter Loftus, reporter for the WSJ, joins us for more on this new drug. Next, phone numbers are quickly becoming the new social security numbers.  Your mobile phone number is becoming the primary way for tech companies like Facebook to identify users and secure your accounts, think two-factor authentication.  Scott Rosenberg, technology editor at Axios, joins us for the big problem, your phone and number are being used like access keys, and how often do you want to give that information away. Finally, R. Kelly has broken his silence on the latest sexual abuse claims against him.  In a nearly 80 minute interview he did with Gayle King from CBS, R. Kelly denies all the allegations, says everyone is lying about him and plays the victim claiming he has too big of a heart. It is an explosive interview and my producer Miranda joins us to break it all down. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

This past year brought us a lot of awareness of new cancer treatments making a difference in people's lives. The Nobel Prize for medicine went to a pair of scientists for their work on cancer. The discoveries of Dr. James Allison and Dr. Tasuku Honjo led to new ways to treat cancer by targeting the body's immune system rather than cancerous tumors themselves. Peter Loftus, Reporter for the WSJ, joins us to talk about the impact of their work in the fight to cure cancer. Next, one of the more bizarre stories to hit the news. It was the story of 11 malnourished children found in a compound in New Mexico. It was weird to begin with, but then took a turn. According to prosecution documents, the remains of a boy were found and the man who is at the center of it all was allegedly training one of the children in the use of an assault rifle in preparation for a future school shooting. National Security analyst Ryan Mauro, joins us for more on this story. Finally, one of the big jerks of the year was a man known as the “dine and dash dater.” He was finally caught after years on the prowl. Paul Gonzales would meet women on dating apps, take them out, order a robust dinner, and then leave and never come back, forcing the women to pay a huge bill. Lauren Strapagiel, reporter for Buzzfeed News, joins us for how much jail time he is facing and what was in all those dinner orders. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

It is Nobel Prize time and this year the award for medicine goes to a pair of scientists for their work on cancer. The discoveries of Dr. James Allison and Dr. Tasuku Honjo led to new ways to treat cancer by targeting the body's immune system rather than cancerous tumors themselves. Peter Loftus, Reporter for the WSJ, joins us for the latest Nobel Prize winners and the impact of their work in the fight to cure cancer. Next, Goodbye NAFTA, hello USMCA! The US, Canada, and Mexico have just agreed to update NAFTA after more than a year of intense negotiations. The deal has a new name, new rules for auto makers, still doesn't take care of current steel and aluminum tariffs, and sets up the next battle with figuring out our trade disputes with China. Megan Casella, trade reporter for Politico, joins us for what's in the deal and the potential fight with Congress to get it all approved. Finally, it has been a whirlwind of news for Elon Musk and Tesla. The Securities and Exchange Commission sued Musk for tweets related to taking Tesla private. Musk caved and now he has to pay $20M, step down as chairman, and hire a lawyer to approve any tweets he sends out related to the company. Ben Geman, Energy Reporter at Axios, joins us on the Elon Musk roller coaster. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

The fight over immigration and the President's policies has created a huge divide that is no longer playing out just in Washington.  President Trump tweeted over the weekend that in order to end illegal immigration people need to be stopped at the border and turned away immediately depriving them of their due process. Press Secretary Sarah Huckabee Sanders was also subjected to the divide when she was asked to leave a Virginia restaurant simply because she defends the President's policies. Daniel Lippman from Politico joins us for the latest. Iconic American brand Harley Davidson announced that because of tariffs imposed by the European Union they will be shifting some of their production overseas. Erica Pandey, reporter for Axios will join us to talk about how Harley Davidson is handling increased costs after being caught in the tariff cross fire. Finally, Marijuana hit a milestone yesterday.  The FDA has approved the first CBD drug derived from the plant. Peter Loftus with the Wall Street Journal will join us to talk about who the drug helps and also about changing federal regulations to remove its schedule 1 classification. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

--{ The Shot that Spluttered Around the World: "The Annual Flu's Here, Howl! Almighty Pain, Mixed Flu Shots from China, Neglecting ol' Brisbane, These Little Pricks with Needle Sticks, Scientific Fight, Say It's Free, Not for Me, the Mix is Never Right, Hype and Fear, the End is Near, Cognitive Dizziness, Mob Runs to be Saved, the Way is Paved with Gold For Vaccine Business" © Alan Watt }-- 9-11, Buildings Destroyed, Economic Bubble - Media, Journalism, No Law Requiring Telling Truth to Public - Propaganda, Paid Advertisements. Movie Industry, Disasters, Gaia's "Revenge" - Cures for Diseases - Pandemics - Flu Shot, Inoculations, Outbreaks, Epidemics, Pneumonia. Canadian Permafrost, Unearthing Live 1918 Flu Virus - Military-Industrial Complex - Influenza Strain Mutations, Gene Splicing - Depopulation, Eugenicists Debating. Hen Farming, Eggs Used in Vaccine Manufacture. Nascent Moon, Sanhedrin, Venus - Hammer and Sickle - Astronomy, Eclipses, Priesthood. Archives of Information, Study of Masses - Religions, Education, Literacy - Computer Interfacing, Virtual Reality, Brain Chip (No More You as Individual), Programming. Financial Bailout, Banks' Use of Taxpayers' Money, No Accountability - Looting Public. (Articles: ["Glaxo Prepares Work Force For Worst-Case Flu Scenario" by Peter Loftus of DOW JONES NEWSWIRES (borsaitaliana.it) - Dec. 23, 2008.] [" 'Killer' Australian flu strain set to spread across UK, experts warn" (dailymail.co.uk) - Dec. 29, 2008.] ["Researchers unlock secrets of 1918 flu pandemic" (reuters.com) - Dec. 29, 2008.] ["Influenza: Battling The Last Great Virus" [Unearthing a deadly mystery] (archives.cbc.ca) - Broadcast Date: March 21, 1997.] ["Where'd the bailout money go? Shhhh, it's a secret" The Associated Press (iht.com) - Dec. 22, 2008.]) *Title/Poem and Dialogue Copyrighted Alan Watt - Dec. 30, 2008 (Exempting Music, Literary Quotes, and Callers' Comments)